Cargando…

The next generation of the World Health Organization's global antiretroviral guidance

The 2013 World Health Organization’s (WHO) Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection provide more than 50 new recommendations across the continuum of HIV care, including recommendations on HIV testing, using antiretroviral drugs for preventi...

Descripción completa

Detalles Bibliográficos
Autores principales: Hirnschall, Gottfried, Harries, Anthony D, Easterbrook, Philippa J, Doherty, Meg C, Ball, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International AIDS Society 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3699697/
https://www.ncbi.nlm.nih.gov/pubmed/23819908
http://dx.doi.org/10.7448/IAS.16.1.18757
_version_ 1782275441157996544
author Hirnschall, Gottfried
Harries, Anthony D
Easterbrook, Philippa J
Doherty, Meg C
Ball, Andrew
author_facet Hirnschall, Gottfried
Harries, Anthony D
Easterbrook, Philippa J
Doherty, Meg C
Ball, Andrew
author_sort Hirnschall, Gottfried
collection PubMed
description The 2013 World Health Organization’s (WHO) Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection provide more than 50 new recommendations across the continuum of HIV care, including recommendations on HIV testing, using antiretroviral drugs for prevention, linking individuals to HIV care and treatment services, initiating and maintaining antiretroviral therapy (ART) and monitoring treatment. Guidance is provided across all age groups and populations of adults, pregnant and breastfeeding women, adolescents and key populations. The guidelines are based on a public health approach to expanding the use of ARV drugs for HIV treatment and prevention, with a particular focus on resource-limited settings. The most important new clinical recommendations include: treating adults, adolescents and older children earlier – starting ART in all individuals with a CD4 cell count of 500 cells/mm(3) or less (but giving priority to those with advanced clinical disease or a CD4 cell count less than 350 cells/mm(3)); starting ART at any CD4 cell count in certain populations, including those with active TB (existing recommendation), Hepatitis B infection and severe chronic liver disease, HIV-positive partners in serodiscordant couples (existing recommendation), pregnant and breastfeeding women, and children younger than 5 years of age; a preferred first-line ART regimen of Tenofovir+3TC or FTC+ Efavirenz as a once-daily fixed-dose combination for adults, pregnant women, and children aged 3 years and older; and the use of viral load testing as the preferred approach to monitoring the response to ART and to diagnose treatment failure. Guidance is also provided on enhancing the efficiency and effectiveness of HIV services, including strategies to improve retention in care, and adherence to ART; task-shifting to address human resource gaps; decentralizing delivery of ART to primary health care, and integrating ART services within maternal and child health, TB or drug dependency clinics. There is additional guidance for programme managers on how to plan HIV programmes and use resources most efficiently.
format Online
Article
Text
id pubmed-3699697
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher International AIDS Society
record_format MEDLINE/PubMed
spelling pubmed-36996972013-07-03 The next generation of the World Health Organization's global antiretroviral guidance Hirnschall, Gottfried Harries, Anthony D Easterbrook, Philippa J Doherty, Meg C Ball, Andrew J Int AIDS Soc Commentary The 2013 World Health Organization’s (WHO) Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection provide more than 50 new recommendations across the continuum of HIV care, including recommendations on HIV testing, using antiretroviral drugs for prevention, linking individuals to HIV care and treatment services, initiating and maintaining antiretroviral therapy (ART) and monitoring treatment. Guidance is provided across all age groups and populations of adults, pregnant and breastfeeding women, adolescents and key populations. The guidelines are based on a public health approach to expanding the use of ARV drugs for HIV treatment and prevention, with a particular focus on resource-limited settings. The most important new clinical recommendations include: treating adults, adolescents and older children earlier – starting ART in all individuals with a CD4 cell count of 500 cells/mm(3) or less (but giving priority to those with advanced clinical disease or a CD4 cell count less than 350 cells/mm(3)); starting ART at any CD4 cell count in certain populations, including those with active TB (existing recommendation), Hepatitis B infection and severe chronic liver disease, HIV-positive partners in serodiscordant couples (existing recommendation), pregnant and breastfeeding women, and children younger than 5 years of age; a preferred first-line ART regimen of Tenofovir+3TC or FTC+ Efavirenz as a once-daily fixed-dose combination for adults, pregnant women, and children aged 3 years and older; and the use of viral load testing as the preferred approach to monitoring the response to ART and to diagnose treatment failure. Guidance is also provided on enhancing the efficiency and effectiveness of HIV services, including strategies to improve retention in care, and adherence to ART; task-shifting to address human resource gaps; decentralizing delivery of ART to primary health care, and integrating ART services within maternal and child health, TB or drug dependency clinics. There is additional guidance for programme managers on how to plan HIV programmes and use resources most efficiently. International AIDS Society 2013-06-30 /pmc/articles/PMC3699697/ /pubmed/23819908 http://dx.doi.org/10.7448/IAS.16.1.18757 Text en © 2013 Hirnschall G et al; licensee International AIDS Society http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Commentary
Hirnschall, Gottfried
Harries, Anthony D
Easterbrook, Philippa J
Doherty, Meg C
Ball, Andrew
The next generation of the World Health Organization's global antiretroviral guidance
title The next generation of the World Health Organization's global antiretroviral guidance
title_full The next generation of the World Health Organization's global antiretroviral guidance
title_fullStr The next generation of the World Health Organization's global antiretroviral guidance
title_full_unstemmed The next generation of the World Health Organization's global antiretroviral guidance
title_short The next generation of the World Health Organization's global antiretroviral guidance
title_sort next generation of the world health organization's global antiretroviral guidance
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3699697/
https://www.ncbi.nlm.nih.gov/pubmed/23819908
http://dx.doi.org/10.7448/IAS.16.1.18757
work_keys_str_mv AT hirnschallgottfried thenextgenerationoftheworldhealthorganizationsglobalantiretroviralguidance
AT harriesanthonyd thenextgenerationoftheworldhealthorganizationsglobalantiretroviralguidance
AT easterbrookphilippaj thenextgenerationoftheworldhealthorganizationsglobalantiretroviralguidance
AT dohertymegc thenextgenerationoftheworldhealthorganizationsglobalantiretroviralguidance
AT ballandrew thenextgenerationoftheworldhealthorganizationsglobalantiretroviralguidance
AT hirnschallgottfried nextgenerationoftheworldhealthorganizationsglobalantiretroviralguidance
AT harriesanthonyd nextgenerationoftheworldhealthorganizationsglobalantiretroviralguidance
AT easterbrookphilippaj nextgenerationoftheworldhealthorganizationsglobalantiretroviralguidance
AT dohertymegc nextgenerationoftheworldhealthorganizationsglobalantiretroviralguidance
AT ballandrew nextgenerationoftheworldhealthorganizationsglobalantiretroviralguidance